Formulation

Formulation and Analytics Platforms Transforming Drug Product Development

David Alvaro, Ph.D.

Pharma's Almanac

Platforms

Built for Speed and Scale: How CDMO Cell Line Platforms Are Reshaping Biologic Development

David Alvaro, Ph.D.

Pharma's Almanac

Next-Gen Biologics

What do you see as the next big modality in biologics, and what factors are driving innovation in this space?

Pharma's Almanac

RNA

What new opportunities are emerging for mRNA technology, and how is the portfolio of applications expanding beyond vaccines?

Pharma's Almanac

AI

Is AI truly transforming drug development, or are we still navigating through the hype?

Pharma's Almanac

Sustainability

How can pharma manufacturing align with green initiatives while maintaining efficiency and compliance?

Pharma's Almanac

Innovation

How is the pharmaceutical industry integrating innovations from adjacent industries to enhance drug development and production?

Pharma's Almanac

Changing Roles

How are Advancements in Technology Reshaping the Roles and Capabilities of CDMOs and CROs in the Drug Development Life Cycle?

Pharma's Almanac

Global Access

How Can (Bio)pharmaceutical Companies Contribute to Improving Global Access to Essential Medications?

Pharma's Almanac

Digitalization

How can Life Science Technology Providers Support the Pharmaceutical Industry in the Transition Toward More Digitally Connected Operations?

Pharma's Almanac

Investment

What are the Current Investment Trends in the Pharmaceutical Industry, and How are They Influencing the Sector’s Direction?

Pharma's Almanac

Commitment to ESG Principles

How can pharmaceutical and biopharmaceutical companies demonstrate their commitment to ESG principles in manufacturing?

Pharma's Almanac

Accelerating Product Development

What strategies are being employed to accelerate product development and commercialization without compromising quality?

Pharma's Almanac

CDMO - Small Biotech

Cis-Targeted Immunotherapies Need Large CDMO Expertise But Also Flexibility

Julie Trulson, Ph.D.

Tech Transfer

Transparent Communication Supports Tech Transfers Of Cis-targeted Immunotherapies

Julie Trulson, Ph.D.

Roundtable

What do you see as the most significant regulatory decision or guidance on the horizon for 2024 (or beyond)?

Pharma's Almanac

Roundtable

What Do You Think Was The Single Most Consequential Event Or Result In Pharma/Biopharma In 2023?

Pharma's Almanac

Real-World Data

How Is Your Organization Currently Leveraging Real-World Data/Evidence and What Uses Do You Anticipate in the Future?

Pharma's Almanac

Industry Wisdom

What Piece of Conventional Industry Wisdom Do You Think is Misguided, Outdated, or Just Plain Wrong?

Pharma's Almanac

International Markets

In what international markets do you anticipate significant developments in the near future?

Pharma's Almanac